19-04-2000

1

3

09/647970 52Sec'd PCT/PTO 060CT 2000




25

CLAIMS

1. An atropo-isomeric chiral phosphorated ligand of formula (I), having C₁

symmetry, in the optically active form or in the racemic form



5 wherein

4

21

6 the atoms A, B, C, D, E and F, equal to or different from one another, are carbon

7 atoms or hetero-atoms chosen from among oxygen, nitrogen and sulphur, which

8 form together an Ar of Het aromatic residue, where Ar is chosen between

9 pentatomic heterocyclic residue and phenyl, and Het is a pentatomic heterocyclic

residue, and where said pentatomic heterocyclic aromatic residue contains 1 or 2

11 hetero-atoms, equal to or different from one another, selected from the group

consisting of -O-, -S- and -NR₃-, wherein $R_3 = H$, an alkyl group, an aromatic

group, a group $-P_1(R_1)_2$, or a nitrogen atom comprised as hetero-atom in the other

pentatomic heterocyclic residue belonging to the structure of formula (I);

l = 0, 1; when l = 1, F is a carbon atom;

 R_1 and R_2 , bound to the phosphorous atoms, equal to or different from one

another, are selected from a linear, branched or cyclic C₃-C₁₀ alkyl group, a

18 carbocyclic aromatic group, and a heterocyclic aromatic group having 5-6

19 members in the cycle, containing one or more hetero-atoms chosen among

20 oxygen, sulphur and nitrogen, where said carbocyclic or heterocyclic aromatic

group is optionally substituted with one or more groups selected from a linear or

22 branched C_1 - C_{10} alkyl group, a linear or branched C_1 - C_{10} alkoxyl group, an

23 halogen, -COOR₄, -SO₃R₄ and -NR₅R₆, where



 R_4 is chosen among H, alkyl, aryl, alkaline or alkaline-earth metal, -NH $_4$ and alkyl

25 ammonium cation having from 4 to 20 carbon atoms; and where R_5 and R_6 , equal

to or different from one another, are H or alkyl; or

27 R₁ and R₂ together with the phosphorus atom, form a heterocycle having 3-6

28 atoms in the cycle, optionally substituted with linear or branched C1-C10 alkyl

29 groups;

30 X is an -O- group or an -N(R_7)- group, where R_7 is chosen among H, alkyl and

31 phenyl;

n is 0 or 1, when Ar is a heterocyclic aromatic residue;

n is 1, when Ar is phenyl;

 Q_1 , Q_2 , Z_1 and Z_2 , equal to or different from one another, are selected from the

group consisting of H, linear, branched or cyclic C₁-C₁₀ alkyl, linear or branched

36 C₁-C₁₀ alkoxyl, phenyl and halogen, or

 Q_1 taken together with Z_1 , or Q_2 taken together with Z_2 , form a carbocyclic

aromatic ring selected from phenyl and naphthyl, said carbocyclic aromatic ring

being optionally substituted with one or more T groups, where T is chosen among

halogen, C_1 - C_{10} alkyl, C_1 - C_{10} alkokyl, -COOR₄, -SO₃R₄ and -NR₅R₆, where R₄ is

selected from H, C₁-C₁₀ alkyl, phenyl, alkaline or alkaline-earth metal, -NH₄ or C₄-

 C_{12} alkyl ammonium cation, and where R_5 and R_6 , equal to or different from one

another, are selected from H and C_{1} - C_{10} alkyl; and wherein

44 $-P_1(R_1)_2$ and $-(X)_n-P_2(R_2)_2$ are bound to the corresponding carbocyclic or

heterocyclic aromatic residue by means of a carbon atom of said aromatic residue

or by means of a nitrogen atom comprised as hetero-atom in a pentatomic

47 heterocyclic residue;

said phosphorated ligand further having:

i) a difference between the residual charges of the phosphorous atoms

 $\Delta Q(P) = Q(P_1) - Q(P_2) > 0.05,$

where Q(P1) and Q(P2) are the values of difference between the number of

valence electrons and the number of electrons actually present for the

phosphorous atoms P₁ and P₂, said difference between residual charges being

calculated using the program MOPAC, Version 6.0, Method MNDO;

ii) a cone angle β_n ("natural bite angle" according to Casey) ranging from 80° to AMENDED SHEET

130°, defined as preferred chelation angle P₁-M-P₂ between the phosphorous 57

atoms P₁ and P₂ and a transition metal M, said angle being obtained by 58

minimization of the strain energy of the fragment M(diphosphine), where M is Rh, 59

and calculated by means of the program SYBYL, using the force field of TRIPOS 60

modified by entering the parameters developed for the Rh-diphosphine complexes 61

by M. Kranenburg et al., in Organometallics, 14, 3081 (1995); 62

iii) an energy barrier value of interconversion between the two enantiomers of a 63

given ligand 64

 $\Delta E = E_{trans} - E_{min} \ge 28 \text{ Kcal/mol}$ 65

where $\mathsf{E}_{\mathsf{trans}}$ is the energy value for the transition state, and $\mathsf{E}_{\mathsf{min}}$ is the value 66

associated to the state of minimum energy of the enantiomers, expressed in 67

Kcal/mol, said ΔE being calculated by using the program MOPAC, Version 6.0, 68

Method MNDO, assuming that the energy of the maximum-energy conformer E_{trans} 69

is that of the conformer in which the two aromatic rings are coplanar. 70

2. The phosphorated ligand according to claim 1, wherein 1

i) said difference $\Delta Q(P) = Q(P_1) - Q(P_2)$ is > 0.15: 2

ii) said "natural bite angle" β_{n} ranging from 83° and 120°. 3

3. The phosphorated ligand according to claim 1, wherein said phosphorated 1

2 ligand is chosen between a ligand of formula (I)a and a ligand of formula (I)b:


$$\begin{array}{c} Q_2 \\ Q_2 \\ C \\ Het_2 \\ E \end{array} \begin{array}{c} Z_2 \\ Xn \\ P_2 \\ R_2 \\ R_1 \\ P_1 \\ R_1 \\ R_1 \\ R_2 \\ R_2 \\ R_1 \\ R_2 \\ R_2 \\ R_2 \\ R_2 \\ R_2 \\ R_3 \\ R_4 \\ R_2 \\ R_2 \\ R_3 \\ R_4 \\ R_4 \\ R_5 \\ R_5 \\ R_6 \\ R_7 \\ R_8 \\ R_8 \\ R_8 \\ R_9 \\ R_9$$

$$R_2$$
 P_2
 Q_2
 R_1
 P_1
 P_1
 Q_2
 Q_2
 Q_2
 Q_2
 Q_2
 Q_3
 Q_4
 Q_4
 Q_4
 Q_4
 Q_5
 Q_5
 Q_5
 Q_5
 Q_5

(I)b

where

- Het, and Het2 are pentatomic heterocyclic aromatic rings, equal to or different from 8
- 9 one another, defined as Het in claim 1;
- n is 0 or 1; 10
- X, A, B, C, D, E, Q_1 , Q_2 , Z_1 and Z_2 are as defined in claim 1. 11
- 4. The phosphorated ligand according to claim 1, wherein said heterocyclic
- residue is selected from the group consisting of thiophene, pyrrole, furan, 2
- imidazole, isoxazole, isothiazole, pyrazole and triazole. 3
- 5. The phosphorated ligand according to claim 1, wherein Q_1 taken together with 1
- Z_1 , or Q_2 taken together with Z_2 , form a carbocyclic ring, and Het is condensed 2
- with phenyl or naphthyl. 3
- 6. The phosphorated ligand according to claim 5, wherein said heterocyclic ring 1
- Het condensed with phenyl is selected from the group consisting of 2
- benzothiophene, naphthothiophene, indole, benzofuran and benzoimidazole. 3
- 7. The phosphorated ligand according to claim 1, wherein said phosphorated 1
- ligand is chosen from a ligand of formula (I)c, (I)d and (I)e: 2




(I)c

$$R_2$$
 P_2
 R_1
 R_1
 R_1
 R_2
 R_1
 R_2
 R_1
 R_2
 R_1
 R_2
 R_3
 R_4
 R_4
 R_4
 R_5
 R_7
 R_7

9

(I)e

- wherein Het, and Het, are defined as Het in claim 1;
- 11 A, B, C, D, E, Q_1 , Z_1 , P_1 , R_1 , Q_2 , Z_2 , P_2 , R_2 and T are as defined in claim 1 for
- 12 formula (I);
- 13 m is 0, 1 or 2.
- 8. The phosphorated ligand according to claim 1, wherein said heterocyclic
- aromatic residue is selected from the group consisting of 2,5-dimethyl-thien-3-yl,
- 3 4,6-dimethyl-benzofur-3-yl, 3-methyl-indol-2-yl, 1-N-methyl-indol-2-yl, and
- benzothien-3-yl; and said carbocyclic aromatic residue is phenyl.
- 9. The phosphorated ligand according to claim 1, wherein said groups $-P_1(R_1)_2$ and
- $_2$ -P₂(R₂)₂ are selected from diphenyl phosphine, dicyclohexyl phosphine, J₁, J₂ and
- J_3 , where J_1 , J_2 and J_3 have the following formulas:



10. The phosphorated ligand according to claim 1, containing one of the following 1 sub-structures: (4-diphenylphosphine)- or (4-dicyclohexylphosphine)-2,5-dimethyl-2 thien-3-yl; (1-N-diphenylphosphine)-3 OF (1-N-dicyclohexylphosphine)-3methylindol-2-yl; (3-diphenylphosphine)-4 or (3-dicyclohexylphosphine)-1-Nmethylindol-2-yl; 2-(diphenylphosphine)- or 2-(dicyclohexylphosphine)-benzothien-5 3-yl; 2-(diphenylphosphine-oxy)- or 2-(dicyclohexylphosphine-oxy)-phenyl-1-yl; 4-6 (diphenylphosphine-oxy)- or 4-(dicyclohexylphosphine-oxy)-2,5-dimethyl-thien-3-7 yl; 4-(2',5'-dimethyl-phospholyl)- or 4-(dibenzophospholyl)-2,5-dimethyl-thien-3-yl; 8 1-N-(2',5'-dimethyl-phospholyl)- or 1-N-(dibenzophospholyl)-3-methyl-indol-2-yl. 9 11. The phosphorated ligand according to claim 1, wherein said phosphorated 10

ligand is chosen from the compounds from (1) to (15).

1 12. Procedure for the preparation of an atropo-isomeric phosphorated ligand of

2 formula (I) having C₁ symmetry, as defined in claim 1, comprising the following

3 steps:

WO 99/52915 PCT/EP99/02432

- a) construction of the molecular model of a series of structures of ligands of
- formula (I), (I)₁, (I)₂, (I)₃, ---, (I)_z, where z is the number of structures created, by
- 6 means of the computation program SYBYL, Version 6.2;
- b) conformational analysis, comprising the determination of the minimum-energy
- 8 conformer for each structure from $(I)_1$ to $(I)_2$, followed by optimisation using the
- 9 program MOPAC, Version 6.0, Method MNDO;
- 10 c) calculation of the difference

$$\Delta Q(P) = Q(P_1) - Q(P_2)$$

- as defined in claim 1, for each minimum-energy conformer structure, by using the
- computation program MOPAC, Version 6.0, Method MNDO;
- 14 d) calculation, for each structure from $(I)_1$ to $(I)_2$, of the value of the energy barrier
- of interconversion between the two enantiomers (atropo-isomers) of formula (I)

$$\Delta E = E_{trans} - E_{min}$$

- as defined in claim 1, made using the computation program MOPAC, Version 6.0,
- 18 Method MNDO, assuming that the value E_{trans} is that of the maximum-energy
- 19 conformer having the two rings Ar and Het of the structure (I) coplanar with
- 20 respect to one another;
- e) calculation, for each structure from (I), to (I), of the "natural bite angle" β_n , as
- defined in claim 1, obtained by minimisation of the strain energy of the fragment
- 23 M(diphosphine), imposing that M should be Rh and that the bending constant of
- 24 the bond P₁-M-P₂ should be 0 Kcal mol⁻¹, and calculated by using the program
- 25 SYBYL, Version 6.2, adopting the parameters of the force field of the program
- TRIPOS, modified by entering the parameters developed for the Rh-diphosphine
- complexes by M. Kranenburg et al., in *Organometallics*, 14, 3081, 1995;
- 28 f) selection of the structures from (I), to (I), having:
- 29 i) $\Delta Q(P) = Q(P_1) Q(P_2) > 0.05$
- i) a "natural bite angle" β_n ranging between 80° and 130°;
- ii) an energy barrier of interconversion between the two enantiomers of the
- same structure $\Delta E \ge 28$ Kcal/mol;
- 33 g) chemical synthesis of the phosphorated ligands of formula (I) thus selected.
- 1 13. The procedure according to claim 12, wherein said step f) consists in a
- selection of the structures from $(I)_1$ to $(I)_2$ having:

- i) the difference $\Delta Q(P) = Q(P_1) Q(P_2) > 0.15$;
- ii) the "natural bite angle" β_n ranging between 83° and 120°.
- 1 14. The procedure according to claim 12, wherein said step g) is carried out
- 2 according to one of the following procedure:
- 3 A) coupling reaction between aromatic or hetero-aromatic halides with
- 4 organometallic aryl or hetero-aryl reactants selected from organolithium,
- organomagnesium, organozinc, and organoboron, in the presence of catalytic
- quantities of salts or complexes of copper, nickel, or palladium; or
- 7 B) cyclisation and aromatisation, with formation of one of the two heterocyclic
- 8 rings comprised in the structure of formula (I), of a precursor already containing
- 9 the other heterocyclic or carbocyclic system;
- in said procedure the introduction of the groups containing the phosphorous atom
- preceding or following the reaction of formation of the inter-annular bond.
- 1 15. The procedure according to claim 14, wherein said introduction of the groups
- 2 containing the phosphorous atom is carried out according one of the following
- 3 reactions:
- in the case of phosphine derivatives:
- 5 Ar-[M] + XP(R₁)₂ \rightarrow Ar-P(R₁)₂
- 6 Ar-[M] + XP(=0) $(R_1)_2 \rightarrow Ar-P(=0)(R_1)_2 \rightarrow Ar-P(R_1)_2$
- 7 Ar-[M] + $(R_2O)_2P(=O)(R_1) \rightarrow Ar_2-P(=O)(R_1) \rightarrow Ar_2-PR_1$
- 8 Ar-X + $ZP(R_1)_2 \rightarrow Ar-P(R_1)_2$
- 9 wherein
- 10 Ar is an aromatic residue comprised in the structure of formula (I);
- [M] is an organometallic group;
- 12 X is a halogen;
- Z is an alkaline metal;
- R_1 and R_2 are alkyl or aryl residues;
- in the case of phosphite or aminophosphine derivatives :
- 16 Ar-OH + $XP(R_1)_2 \rightarrow Ar-OP(R_1)_2$
- 17 Ind-NZ + $XP(R_1)_2 \rightarrow Ind-NP(R_1)_2$
- 18 Ind-NZ + XP(=0)(R₁)₂ \rightarrow Ind-NP(=0)(R₁)₂ \rightarrow Ind-NP(R₁)₂

- 19 Ar-NHR₂ + XP(R₁)₂ \rightarrow Ar-NR₂P(R₁)₂
- 20 Ar-X + $ZOP(R_1)_2 \rightarrow Ar-OP(R_1)_2$
- 21 Ar is a carbocyclic aromatic or hetero-aromatic residue comprised in the structure
- of formula (I);
- 23 Ind is an indole residue;
- 24 X is a halogen;
- 25 Z is an alkaline metal;
- 26 R, is an alkyl or aryl group;
- 27 R₂ is H or an alkyl or aryl group.
 - 1 16. The procedure according to claim 14, further comprising the resolution of a
- 2 ligand of formula (I) into its optical antipodes, via separation on chromatographic
- 3 column or through a membrane, using a chiral stationary substrate or a chiral
- 4 eluent, or via fractioned crystallisation of a corresponding diastereo-isomeric
- 5 adduct.
- 1 17. The procedure according to claim 16, wherein, if the ligand of formula (I)
- 2 comprises basic or acidic groups, the diastereo-isomeric adduct is the
- 3 corresponding salt with an entantiomerically pure chiral acid or base; alternatively,
- 4 the said adduct is the diastereo-isomeric salt between an enantiomerically pure
- 5 chiral acid and the phosphinoxide corresponding to the present phosphorated
- 6 ligand. In this case, the optical resolution is followed by reduction of optically
- active phosphinoxides into phosphines, via treatment with a reducing agent.
 - 18. An organometallic complex, comprising a chiral phosphorated ligand of formula (I) as defined in each of the claims from 1 to 11, in the enanatiomerically
- 3 pure or enriched form, and a transition metal.
- 19. The organometallic complex according to claim 18, wherein the transition
- metal is selected from the group consisting of Rh, Ru, Ir, Pt, Pd and Ni.
- 20. Use of an organometallic complex according to claim 18 for the preparation of
- an optically active chiral catalyst.
- 21. Procedure for the preparation of an organic compound in the form of stereo-
- 2 isomer, comprising at least one stereoselective reaction conducted in the
- presence of at least one organometallic complex as defined in claim 18.
- 22. The procedure according to claim 21, wherein said stereoselective reaction is

WO 99/52915 PCT/EP99/02432

- 2 selected from the group consisting of enantio- and/or diastereoselective reactions
- of reduction, hydroformylation, hydroboration, hydrosilylation, hydrocyanation,
- allylation, vinylation and other reactions of formation of the C-C bond.